5.47 USD
+0.20
3.80%
At close Feb 21, 4:00 PM EST
After hours
5.50
+0.03
0.55%
1 day
3.80%
5 days
1.11%
1 month
-8.99%
3 months
16.14%
6 months
-2.84%
Year to date
-7.13%
1 year
-11.92%
5 years
-81.78%
10 years
-81.78%
 

About: FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company markets and sells its products in the United States. Sales are generated through the Company's digital platforms.

Employees: 354

0
Funds holding %
of 7,139 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

817% more call options, than puts

Call options by funds: $12.8M | Put options by funds: $1.4M

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

3.28% less ownership

Funds ownership: 77.62% [Q3] → 74.34% (-3.28%) [Q4]

10% less funds holding

Funds holding: 185 [Q3] → 166 (-19) [Q4]

13% less capital invested

Capital invested by funds: $858M [Q3] → $743M (-$114M) [Q4]

31% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 42

39% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 67

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$4.50
18%
downside
Avg. target
$5.75
5%
upside
High target
$7
28%
upside

2 analyst ratings

positive
0%
neutral
50%
negative
50%
Telsey Advisory Group
Dana Telsey
49% 1-year accuracy
94 / 190 met price target
28%upside
$7
Market Perform
Maintained
20 Feb 2025
Goldman Sachs
Brooke Roach
65% 1-year accuracy
24 / 37 met price target
18%downside
$4.50
Sell
Maintained
10 Dec 2024

Financial journalist opinion

Neutral
Business Wire
2 weeks ago
FIGS Announces Date of Fourth Quarter and Full Year 2024 Earnings Release, Conference Call and Webcast
SANTA MONICA, Calif.--(BUSINESS WIRE)--FIGS, Inc. (NYSE: FIGS), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025, after U.S. markets close. FIGS management will host a conference call that day at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial and business results and outlook. Prior to the call, FIGS will publish a f.
FIGS Announces Date of Fourth Quarter and Full Year 2024 Earnings Release, Conference Call and Webcast
Negative
Reuters
1 month ago
Scrubs maker Figs rebuffs Story3 Capital's take-private offer
Figs said on Thursday it has rebuffed private equity firm Story3 Capital Partners' offer to acquire the scrubs maker.
Scrubs maker Figs rebuffs Story3 Capital's take-private offer
Positive
Invezz
1 month ago
Figs stock price sits in a range: will it have a breakout in 2025?
Figs stock has lost momentum and remained in a consolidation phase in almost two years. It remained inside the support and resistance levels at $4.42 and $6.97 in this period, missing the strong stock surge in the United States.
Figs stock price sits in a range: will it have a breakout in 2025?
Neutral
Business Wire
2 months ago
Applied Fundamental Research Issues Open Letter to FIGS Management and its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Applied Fundamental Research, a long-term shareholder of FIGS, Inc. (NYSE: FIGS), has submitted an open letter to the company's management and its Board of Directors. The letter highlights FIGS' exceptional achievements in transforming the healthcare apparel market, expresses confidence in the company's ability to execute its growth strategy as a public company, and outlines recommendations for defining a clear capital allocation strategy to unlock shareholder.
Applied Fundamental Research Issues Open Letter to FIGS Management and its Board of Directors
Neutral
Business Wire
2 months ago
FIGS Announces Updates to Board of Directors
SANTA MONICA, Calif.--(BUSINESS WIRE)--FIGS, Inc. (NYSE: FIGS) (the “Company”), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today announced the appointment of Melanie Whelan, former Chief Executive Officer of SoulCycle Inc., to its board of directors (the “Board”), effective January 1, 2025 (the “Effective Date”). Ms. Whelan joins the Board as an independent director. Ms. Whelan has also been appointed to serve as Chair of the Board'.
FIGS Announces Updates to Board of Directors
Positive
Seeking Alpha
2 months ago
FIGS: Opportunistic Bid Grossly Undervalues A Recession Proof Business
An opportunistic offer by a PE fund during a 'retail lull' grossly undervalues FIGS, thus providing a chance for value and arbitrage investors to profit from the situation. Founded by Heather Hasson and Trina Spear, the stock has dropped from over $35 to $6.07 since its 2021 IPO and subsequent takeover offer. Story3 Capital's $6 per share offer to take the company private undervalues the business, which has strong free cash flow and no debt.
FIGS: Opportunistic Bid Grossly Undervalues A Recession Proof Business
Neutral
The Motley Fool
2 months ago
Is Figs a Buy After $1 Billion Buyout Rumors?
Shares of Figs (FIGS -3.85%) jumped this week after the company reportedly received a buyout offer for around $1 billion. In this video, Travis Hoium shows why private equity buyers may be interested and what the stock could do now.
Is Figs a Buy After $1 Billion Buyout Rumors?
Positive
WSJ
2 months ago
Medical-Apparel Maker Figs Gets Takeover Bid From Private-Equity Firm
The Story3 proposal values the company at more than $1 billion.
Medical-Apparel Maker Figs Gets Takeover Bid From Private-Equity Firm
Positive
WSJ
2 months ago
Medical-Apparel Maker Figs Gets Takeover Bid From Private-Equity Firm
The Story3 proposal values the company at more than $1 billion.
Medical-Apparel Maker Figs Gets Takeover Bid From Private-Equity Firm
Negative
Seeking Alpha
3 months ago
FIGS Back To Q1 Prices, But The Name Is Still A Hold
Figs reported disappointing 3Q24 results with a 2% revenue decline and a 13 percentage point drop in adjusted EBITDA margins, leading to a 30% stock price drop. The company's high SG&A expenses and lack of growth make it difficult to compete against lower-priced alternatives, justifying my Hold rating. Questionable $25 million investment in a pre-product healthcare education app raises concerns about capital allocation and potential conflicts of interest.
FIGS Back To Q1 Prices, But The Name Is Still A Hold
Charts implemented using Lightweight Charts™